Search

Your search keyword '"receptor activator of nuclear factor-κB ligand (RANKL)"' showing total 72 results

Search Constraints

Start Over You searched for: Descriptor "receptor activator of nuclear factor-κB ligand (RANKL)" Remove constraint Descriptor: "receptor activator of nuclear factor-κB ligand (RANKL)"
72 results on '"receptor activator of nuclear factor-κB ligand (RANKL)"'

Search Results

1. Exploring the therapeutic potential of isoorientin in the treatment of osteoporosis: a study using network pharmacology and experimental validation

Catalog

Books, media, physical & digital resources

3. Polysaccharides Derived from Drynaria fortunei Attenuated Osteoclast Differentiation Induced by Receptor Activator of Nuclear Factor-κB Ligand by Modulating NFATc1 and c-Fos.

4. Polysaccharides Derived from Drynaria fortunei Attenuated Osteoclast Differentiation Induced by Receptor Activator of Nuclear Factor-κB Ligand by Modulating NFATc1 and c-Fos

5. Isoliensinine Suppresses Osteoclast Formation Through NF-κB Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss.

6. A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation via Suppressing c-Fos-NFATc1 Signaling Pathway

7. A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation via Suppressing c-Fos-NFATc1 Signaling Pathway.

8. MicroRNA‐21 promotes orthodontic tooth movement by modulating the RANKL/OPG balance in T cells.

10. Deciphering the Cell-Specific Effect of Osteoblast-Macrophage Crosstalk in Periodontitis.

11. Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

12. In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation.

13. A Nitrobenzoyl Sesquiterpenoid Insulicolide A Prevents Osteoclast Formation

14. Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits.

15. RELAXIN enhances differentiation and matrix mineralization through Relaxin/insulin-like family peptide receptor 2 (Rxfp2) in MC3T3-E1 cells in vitro.

16. A monoclonal antibody ameliorates local inflammation and osteoporosis by targeting TNF-α and RANKL.

17. A versatile method for protein-based antigen bioanalysis in non-clinical pharmacokinetics studies of a human monoclonal antibody drug by an immunoaffinity liquid chromatography–tandem mass spectrometry.

18. Fisetin antagonizes cell fusion, cytoskeletal organization and bone resorption in RANKL-differentiated murine macrophages.

19. Osterix/Sp7 regulates biomineralization of otoliths and bone in medaka (Oryzias latipes).

20. Homocysteine alters the osteoprotegerin/RANKL system in the osteoblast to promote bone loss: pivotal role of the redox regulator forkhead O1.

21. Bone mineral density and bone metabolism in patients with major depressive disorder without somatic comorbidities.

22. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.

23. Beclin 1 interactome controls the crosstalk between apoptosis, autophagy and inflammasome activation: Impact on the aging process.

24. Prevention and Treatment of Myeloma Bone Disease.

25. Stochastic differentiation into an osteoclast lineage from cloned macrophage-like cells

26. Increased vitamin D-driven signalling and expression of the vitamin D receptor, MSX2, and RANKL in tooth resorption in cats.

27. Over-expression of receptor activator of nuclear factor-κB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty

28. Up-regulation of osteolytic mediators in human osteosarcoma cells stimulated with nicotine.

29. Experimental periodontitis in mice selected for maximal or minimal inflammatory reactions: increased inflammatory immune responsiveness drives increased alveolar bone loss without enhancing the control of periodontal infection.

30. OPG/RANK/RANKL signaling system and its significance in nephrology.

31. The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse

32. Receptor activator of nuclear factor-kappa B ligand induces osteoclast formation in RAW 264.7 macrophage cells via augmented production of macrophage–colony-stimulating factor.

33. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-κB ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis

34. Bacterial lipopolysaccharide induces osteoclast formation in RAW 264.7 macrophage cells

35. Effects of different magnitudes of mechanical strain on Osteoblasts in vitro

36. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio.

37. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology

38. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.

39. Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-κB ligand

40. Regulation of receptor activator of nuclear factor-κB ligand and osteoprotegerin mRNA expression by parathyroid hormone is predominantly mediated by the protein kinase a pathway in murine bone marrow cultures.

41. Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones.

42. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice

43. A Novel Interaction between Thyroid Hormones and 1,25(OH)2D3 in Osteoclast Formation

44. Isoliensinine Suppresses Osteoclast Formation Through NF-κB Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss.

45. Denosumab-Induced Immune Hepatitis

46. ISG15 Regulates RANKL-Induced Osteoclastogenic Differentiation of RAW264 Cells

47. Denosumab-Induced Immune Hepatitis.

48. In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation

49. Gypenoside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB, AKT, and MAPK signaling pathways.

50. In Vitro and In Vivo Effects of Gracilaria verrucosa Extracts on Osteoclast Differentiation.